Evaluation of the Efficacy and Safety of Rifaximin in Combination With N-acetylcysteine (NAC) in Adult Patients With Irritable Bowel Syndrome With Diarrhea

Unknown Phase 1,Phase 2 NCT04557215

Study Description

Randomized, prospective proof of concept, double-blind, single site clinical trial to determine the efficacy of combined rifaximin and N-acetylcysteine (NAC) therapy vs. rifaximin alone in decreasing clinical symptoms in subjects with IBS-D.

Study Details

Registry ID:: NCT04557215
Conditions:: Irritable Bowel Syndrome With Diarrhea
Phase:: Phase 1,Phase 2
Target Enrollment:: 45 participants
Start Date:: November 13, 2020
Age Range:: 18–75 years
Healthy Volunteers:: No

Study Locations (1 site)

Cedars-Sinai Medical Center
Los Angeles, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →